2,728
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Identification of a blockade epitope of human norovirus GII.17

, , , , , ORCID Icon, & ORCID Icon show all
Pages 954-963 | Received 05 Mar 2021, Accepted 28 Apr 2021, Published online: 18 May 2021

References

  • Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003;9(5):548–553.
  • Jiang X, Wang M, Wang K, et al. Sequence and genomic organization of Norwalk virus. Virology. 1993;195(1):51–61.
  • Xi JN, Graham DY, Wang KN, et al. Norwalk virus genome cloning and characterization. Science. 1990;250(4987):1580–1583.
  • Hardy ME. Norovirus protein structure and function. FEMS Microbiol Lett. 2005 Dec 1;253(1):1–8.
  • Huang P, Farkas T, Marionneau S, et al. Noroviruses bind to human ABO, lewis, and secretor histo-blood group antigens: Identification of 4 Distinct strain-specific patterns. J Infect Dis. 2003;188(1):19–31.
  • Hutson AM, Atmar RL, Estes MK. Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol. 2004;12(6):279–287.
  • Tan M, Jiang X. Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. Trends Microbiol. 2005;13(6):285–293.
  • Tan M, Jiang X. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog. 2010;6(8):e1000983.
  • Tan M, Jiang X. Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol. 2011;19(8):382–388.
  • Tan M, Jiang X. Histo-blood group antigens: a common niche for norovirus and rotavirus. Expert Rev Mol Med. 2014 Mar 10;16(e5).
  • Reeck A, Kavanagh O, Estes MK, et al. Serological Correlate of protection against norovirus-induced gastroenteritis. J Infect Dis. 2010;202(8):1212–1218.
  • Vega E, Barclay L, Gregoricus N, et al. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. J Clin Microbiol. 2014 Jan;52(1):147–155.
  • Bull RA, White PA. Mechanisms of GII.4 norovirus evolution. Trends Microbiol. 2011;19(5):233–240.
  • van Beek J, Ambert-Balay K, Botteldoorn N, et al. Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II.4, late 2012. Euro Surveillance Bulletin. 2013 Jan 3;18(1):8–9.
  • Siebenga JJ, Lemey P, Kosakovsky Pond SL, et al. Phylodynamic reconstruction reveals norovirus GII.4 epidemic expansions and their molecular determinants. PLoS Pathog 2010;6(5):e1000884.
  • Siebenga JJ, Vennema H, Renckens B, et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol. 2007;81(18):9932–9941.
  • Noel JS, Fankhauser RL, Ando T, et al. Identification of a Distinct common strain of “norwalk-like viruses” having a global distribution.. J Infect Dis. 1999;179(6):1334–1344.
  • Chhabra P, de Graaf M, Parra GI, et al. Updated classification of norovirus genogroups and genotypes. J Gen Virol. 2019;100(10):1393–1406.
  • Zhang XF, Huang Q, Long Y, et al. An outbreak caused by GII.17 norovirus with a wide spectrum of HBGA-associated susceptibility. Sci Rep. 2015;5:17687.
  • Matsushima Y, Ishikawa M, Shimizu T, et al. Genetic analyses of GII.17 norovirus strains in diarrheal disease outbreaks from December 2014 to March 2015 in Japan reveal a novel polymerase sequence and amino acid substitutions in the capsid region. Euro Surv Bull. 2015 Jul 2;20(26):21173.
  • Lee CC, Feng Y, Chen SY, et al. Emerging norovirus GII.17 in Taiwan. Clin Infect Dis. 2015;61(11):1762–1764.
  • Fu J, Ai J, Jin M, et al. Emergence of a new GII.17 norovirus variant in patients with acute gastroenteritis in jiangsu, China, September 2014 to March 2015. Euro Surv Bull. 2015;20(24):21157.
  • Chan MC, Lee N, Hung TN, et al. Rapid emergence and predominance of a broadly recognizing and fast-evolving norovirus GII.17 variant in late 2014. Nat Commun. 2015;6:10061.
  • de Graaf M, van Beek J, Vennema H, et al. Emergence of a novel GII.17 norovirus – End of the GII.4 era? Euro Surveillance Bulletin. 2015;20(26):21178.
  • Parra GI, Squires RB, Karangwa CK, et al. Static and evolving norovirus genotypes: implications for epidemiology and immunity. PLoS Pathog. 2017;13(1):e1006136.
  • Lindesmith LC, Kocher JF, Donaldson EF, et al. Emergence of novel human norovirus GII.17 strains correlates With changes in blockade antibody epitopes. J Infect Dis. 2017;216(10):1227–1234.
  • Lu J, Fang L, Zheng H, et al. The evolution and transmission of epidemic GII.17 noroviruses. J Infect Dis. 2016;214(4):556–564.
  • Wang HB, Wang Q, Zhao JH, et al. Complete nucleotide sequence analysis of the norovirus GII.17: A newly emerging and dominant variant in China, 2015. Infect Genet Evol. 2016;38:47–53.
  • Chen H, Qian F, Xu J, et al. A novel norovirus GII.17 lineage contributed to adult gastroenteritis in shanghai, China, during the winter of 2014–2015. Emerg Microbes Infect. 2015;4(11):e67.
  • Singh BK, Koromyslova A, Hefele L, et al. Structural evolution of the emerging 2014-2015 GII.17 noroviruses. J Virol. 2016;90(5):2710–2715.
  • Qian Y, Song M, Jiang X, et al. Structural adaptations of norovirus GII.17/13/21 lineage through Two Distinct evolutionary paths. J Virol. 2019;93(1):e01655–18.
  • Zhang C, Ku Z, Liu Q, et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33(20):2335–2341.
  • Wang X, Ku Z, Dai W, et al. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice. Vaccine. 2015;33(43):5779–5785.
  • Wang X, Wang S, Zhang C, et al. Development of a surrogate neutralization assay for norovirus vaccine evaluation at the cellular level. Viruses. 2018;10(1):27.
  • Zhang C, Wang Y, Zhu Y, et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nat Commun. 2021;12(1):1–16.
  • Rockx BH, Vennema H, Hoebe CJ, et al. Association of histo-blood group antigens and susceptibility to norovirus infections. J Infect Dis. 2005;191(5):749–754.
  • Hutson AM, Atmar RL, Graham DY, et al. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis. 2002;185(9):1335–1337.
  • Lindesmith LC, Beltramello M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012;8(5):e1002705.
  • Debbink K, Donaldson EF, Lindesmith LC, et al. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol. 2012;86(2):1214–1226.
  • Debbink K, Lindesmith LC, Donaldson EF, et al. Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses. J Virol. 2014;88(13):7256–7266.
  • Tohma K, Lepore CJ, Gao Y, et al. Population genomics of GII.4 noroviruses reveal complex diversification and New antigenic sites involved in the emergence of pandemic strains. mBio. 2019;10(5):e02202–19.